Physician profile
Nancy D Ludwick
NPI 1669920195
$3,086.30
in general payments reported to CMS, 2019-2025
25 companies · $960 in 2025
The $960 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $747 · 2023: $628 · 2024: $578 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,030 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.22 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $804.64 | 2022-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $469.21 | 2021-2025 | |
| Harmony Biosciences LLC | $278.24 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $183.44 | 2023-2025 | Sunosi |
| Medtronic, INC. | $140.96 | 2021-2023 | Linq II |
| Novo Nordisk INC | $121.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.46 | 2021 | |
| Incyte Corporation | $115.64 | 2024 | Opzelura |
| Neurent Medical Limited | $114.63 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Phathom Pharmaceuticals, INC. | $110.57 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $101.53 | 2022 | |
| Azurity Pharmaceuticals, INC. | $77.36 | 2023-2024 | Horizant, Horizant |
| 3b Medical, INC. | $66.89 | 2025 | Luna |
| Avadel Cns Pharmaceuticals, LLC | $64.43 | 2023-2025 | Lumryz |
| Insmed, INC. | $43.27 | 2025 | Arikayce, Brinsupri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.84 | 2023-2025 | Ofev |
| Fisher & Paykel Healthcare INC | $32.79 | 2024-2025 | Fisher & Paykel Healthcare |
| Astrazeneca Pharmaceuticals LP | $32.41 | 2023-2025 | Tezspire, Wainua |
| Noctrix Health, INC. | $30.48 | 2025 | Nidra |
| Idorsia Pharmaceuticals US INC | $30.09 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $30.08 | 2024 | Trelegy Ellipta, Arexvy |
| Verona Pharma, INC. | $22.85 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $19.62 | 2025 | Zepbound |
| Electromed, INC. | $19.12 | 2025 | Smartvest |
| Genzyme Corporation | $17.64 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Ludwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.